Table 2. Published clinical cases follow-up after switching to second-line TKI after acute imatinib hepatitis in CML patients .

CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor

Authors, publication year	Clinical case	Second-generation TKI
Perini G.F. and co-authors (2009) [13]	A 47-year-old CML woman with imatinib acute hepatotoxicity, which required successful liver transplantation	Treated with nilotinib without the recurrence of the liver injury
Spataro V. (2011) [14]	A 41-year-old woman with CML and postnecrotic imatinib-induced liver cirrhosis	Treated with nilotinib without the recurrence of the liver injury. the complete cytogenic response and major molecular response were achieved after one year
Harding D.J. and co-authors (2016) [15]	A 30-year-old CML woman with imatinib-induced fulminant liver failure which required successful liver transplantation	Treated with dasatinib at the standard 100 mg dose per day, then after two weeks, this dosage was decreased to 50 mg because of QTc interval prolongation associated with the dasatinib-induced inhibition of tacrolimus metabolism via the CYP3A4. Six months after the administration of dasatinib, the patient's BCR-ABL1 decreased to 0.37%, which was consistent with a major molecular response. Liver function tests remained normal.
Nacif L.S. and co-authors (2018) [16]	A 36-year woman with CML and the imatinib acute hepatotoxicity, which required liver transplantation	Treated with dasatinib due to the secondary myocardiopathy, 60 mg/day. No adverse effects were observed, and the patient’s BCR-ABL1 transcript reduced to 10.64% after two months
Lopina N. and co-authors (2018) [17]	A 56-year woman with CML and the imatinib acute hepatotoxicity	Treated with nilotinib in reduced dose (300 mg per day) without the recurrence of the liver injury. A major molecular response was achieved in six months.